Valuation: Acusphere, Inc.

Market Cap 3.46M 3.04M 2.86M 2.61M 4.88M 332M 4.92M 34.34M 13.31M 169M 13.01M 12.73M 549M P/E 2006
-1.06x
P/E 2007 -0.49x
Enterprise Value -11.29M -9.91M -9.32M -8.52M -15.92M -1.08B -16.04M -112M -43.39M -552M -42.41M -41.48M -1.79B EV / Sales 2006
9,811,030x
EV / Sales 2007 5,744,305x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
1 day+99,900.00%
1 week+99,900.00%
Current month+99,900.00%
1 month+99,900.00%
3 months+99,900.00%
6 months+99,900.00%
Current year+99,900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.03
10 years 0
Extreme 1.0E-6
0.25
Change 5-day change 1-year change 3-year change Capi.($)
+99,900.00%+99,900.00%+99,900.00%+99,900.00% 4
+1.01%+1.63%+13.44%+64.70% 46.34B
-1.02%-2.67%+38.33%+108.43% 37.12B
+0.67%+6.47%+12.98%+96.46% 12.13B
-0.08%+2.37%-10.32%+16.62% 11.7B
-0.19%-0.38%+19.35%+139.81% 8.99B
+0.56%+0.56%+26.32%+39.61% 7.25B
+0.55%+4.36%+22.66%+208.30% 7.27B
-0.06%+1.51%+38.94%-16.76% 7.13B
-0.64%+4.66%-40.29%+10.76% 5.16B
Average +9,990.08%+1.45%+10,002.14%+10,056.79% 14.31B
Weighted average by Cap. +0.13%+0.72%+18.74%+79.54%

Financials

2006 2007
Net sales 1.78 1.56 1.47 1.34 2.51 170.6 2.53 17.65 6.84 86.98 6.69 6.54 282.01 2.67 2.34 2.2 2.01 3.76 255.48 3.79 26.43 10.25 130.25 10.02 9.8 422.31
Net income -61.09M -53.62M -50.4M -46.08M -86.11M -5.85B -86.75M -605M -235M -2.98B -229M -224M -9.67B -53.73M -47.16M -44.33M -40.53M -75.73M -5.15B -76.3M -532M -206M -2.62B -202M -197M -8.51B
Net Debt -52.87M -46.41M -43.62M -39.88M -74.53M -5.06B -75.08M -524M -203M -2.58B -199M -194M -8.37B -14.76M -12.95M -12.18M -11.13M -20.8M -1.41B -20.96M -146M -56.7M -721M -55.42M -54.21M -2.34B
Logo Acusphere, Inc.
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Employees
-
  1. Stock Market
  2. Stocks
  3. ACUS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!